Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

Trial Profile

Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs PT 20 (Primary)
  • Indications Hypophosphataemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PEACH
  • Sponsors Phosphate Therapeutics
  • Most Recent Events

    • 07 May 2015 Primary endpoint has been met (To assess the effect of oral PT20 over placebo on serum phosphate) according to a Phosphate Therapeutics media release.
    • 07 May 2015 Results published in the Phosphate Therapeutics Media Release.
    • 29 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top